All G Partners with Armor Protéines to Commercialize Lactoferrin, Secures $6.6 Million Funding

In a significant development for the alternative protein industry, Australian startup All G has secured $6.6 million in funding and formed a joint venture with French dairy ingredients expert Armor Protéines. The collaboration, which was officially announced on December 8, 2025, aims to scale the production of human and bovine lactoferrin through precision fermentation.

The venture pairs All G’s expertise in recombinant proteins with Armor Protéines’ specialized knowledge of bioactive milk proteins, including lactoferrin. The first product launch, recombinant bovine lactoferrin, is slated for Q1 2026, followed by human lactoferrin later in the year. By leveraging Armor Protéines’ extensive distribution channels and scientific capabilities, All G hopes to reach new markets in infant nutrition, adult supplements, and personal care.

The funding, raised via a convertible note from investors such as Agronomics and Döhler Ventures, will be pivotal as All G prepares to launch its Series B round. The company is positioning itself to capitalize on the growing demand for lactoferrin, a protein known for its anti-microbial and immune-boosting properties, which has seen limited availability due to the high cost and difficulty of extracting it from milk.

Historically, lactoferrin has only been available in small quantities because of the challenges associated with isolating it from large volumes of milk. However, by using genetically engineered microbes in fermentation tanks, All G aims to overcome these barriers and unlock new commercial applications. According to CEO Jan Pacas, the company’s technology has already overcome several key technical hurdles, such as replicating native glycosylation patterns and achieving commercially viable production yields. This innovation enables the production of lactoferrin with high purity, consistent quality, and scalable output.

Unlike many players in the alternative protein sector, All G is not creating entirely new markets but rather filling a gap in an already-established market for lactoferrin, where demand exceeds supply. Armor Protéines, a subsidiary of Savencia, one of the world's top producers of bovine lactoferrin, has long-standing relationships with leading players in infant formula and adult nutrition. All G sees the partnership as an opportunity to leverage these connections for rapid revenue growth.

In terms of regulatory progress, All G has secured self-GRAS (Generally Recognized As Safe) status in the United States for its products in adult nutrition. Additionally, the company has gained approval for sales in China in multiple categories, with more filings underway. On the manufacturing side, All G plans to scale production through a contract manufacturer in China and is also negotiating with another CMO in the US or Europe for expanded capacity.

The company is targeting the infant formula market, a $35 billion industry in China, as a major opportunity for human lactoferrin. While All G does not yet have approval to sell into this market, Jan Pacas is optimistic about the future. He predicts that in the next five to 10 years, human lactoferrin will become a dominant ingredient in infant formula, much like human milk oligosaccharides (HMOs), which have already been incorporated into many formulas made via precision fermentation.

Although recombinant casein production is also a part of All G’s research portfolio, lactoferrin is currently the company’s primary focus due to its higher price point and significant consumer interest. Pacas emphasized that for applications like infant formula, the benefits of human-derived proteins, such as human casein, are evident.

The partnership between All G and Armor Protéines marks a pivotal moment in the alternative protein sector, one that could redefine how consumers access high-quality bioactive ingredients. If successful, it could open the doors to a broader range of nutritional, cosmetic, and therapeutic products.